Quarterly ResultApr 30, 2026, 04:45 PM
SMMT Q1 Net Loss $(189.4)M; HARMONi-6 OS Data at ASCO; BLA Accepted
AI Summary
Summit Therapeutics Inc. reported its Q1 2026 financial results and provided significant clinical updates for ivonescimab. Key highlights include the upcoming presentation of HARMONi-6 overall survival data at the ASCO 2026 Plenary Session and the FDA's acceptance of the Biologics License Application (BLA) for ivonescimab with a PDUFA date of November 14, 2026. The company also updated on HARMONi-3 trial progress, expecting final PFS data for the squamous cohort in H2 2026 and for the non-squamous cohort in H1 2027. Financially, Summit reported a GAAP net loss of $(189.4) million and a non-GAAP net loss of $(116.6) million for the quarter, with cash and short-term investments totaling $598.7 million.
Key Highlights
- HARMONi-6 overall survival data to be presented at ASCO 2026 Plenary Session on May 31, 2026.
- FDA accepted BLA for ivonescimab in EGFR-mutated NSCLC with PDUFA goal date of November 14, 2026.
- HARMONi-3 Squamous cohort final PFS data expected in H2 2026; interim analysis recommended continuation.
- HARMONi-3 Non-Squamous cohort PFS data expected in H1 2027, enrollment to complete by Q2 2026 end.
- Q1 2026 GAAP Net Loss was $(189.4) million, up from $(62.9) million in Q1 2025.
- Q1 2026 Non-GAAP Net Loss was $(116.6) million, up from $(51.8) million in Q1 2025.
- Cash and equivalents were $598.7 million at March 31, 2026, down from $713.4 million at Dec 31, 2025.
- Q1 2026 GAAP Operating Expenses were $195.2 million, up from $66.8 million in Q1 2025.